THYMUSKIN - solves thin hair problems.

Clinical tests

Androgenetic Alopecia

A multicentric study8 was undertaken investigating the effectiveness and tolerability of Thymuskin (serum and shampoo) in the initial phase of androgenetic alopecia (AGA) and chronic telogen effluvium (chronic TE) over a period of six months. The study included 364 test subjects split as follows:

  • 70 men (average age 30.7) with AGA
  • 57 men (average age 35.9) with chronic TE
  • 53 women (average age 42.1) with AGA
  • 184 women (average age 36.9) with chronic TE

The patients used the serum once a day and the shampoo three times a week over a total period of 24 weeks. All test subjects underwent a pull test and a symptom evaluation (seborrhoea, erythema and itching) performed by the investigator. Tolerability and cosmetic acceptance/tolerance were also assessed. After six months of treatment, patients with AGA and patients with chronic TE both demonstrated a significant decrease in hair loss, a stimulation of hair growth and a reduction in the symptoms of seborrhoea, erythema and itching. Tolerability and cosmetic acceptance were good tovery good in the majority of patients.

1. Reduction in hair loss8

Hair loss assessment in pull test

2. Decrease in seborrhoea and erythema8

  • Seborrhoea and erythema improvement in 93% and 97% of women respectively
  • Seborrhoea and erythema improvement in 89% and 90% of men respectively
Seborrhoea and erythema symptom improvement

3. Elimination of itching8

  • Itching eliminated in 74% of women (25/34), with the remaining 26% (9/34) still experiencing light itching
  • Itching eliminated in 75% of men (36/48), with the remaining 25% (12/48) still experiencing light itching
  • Strong itching completely eliminated for the total of 3 cases of women and 11 cases of men
Seborrhoea and erythema symptom improvement

THYMUSKIN® effectiveness in patients with androgenetic alopecia8

  • Hair loss reduced in an average of 96% of patients
  • Seborrhoea and erythema improved in at least 89% of patients in each case
  • Itching eliminated in 74% of women and 75% of men

Chronic telogen effluvium

A multicentric study8 (see page 7) was undertaken investigating the effectiveness and tolerability of Thymuskin (serum and shampoo) in 184 women and 57 men with chronic telogen effluvium (chronic TE) over a period of six months.

1. Reduction in hair loss8

99% of women (182/184) and 98% of men (56/57) demonstrated an improvement in the pull test

Hair loss assessment in pull test

2. Seborrhoea and erythema improvement8

  • Seborrhoea and erythema improvement in 93% and 97% of women respectively
  • Seborrhoea and erythema improvement in 89% and 90% of men respectively
Seborrhoea and erythema symptom improvement

3. Elimination of itching8

  • Itching eliminated in 80% of women (92/115), with 17% (20/115) still experiencing light itching and 3% (3/115) still experiencing moderate itching
  • Itching eliminated in 51% of men (21/41), with 39% (16/41) still experiencing light itching and 10% (4/41) still experiencing moderate itching
Assessment of itching sym-ptoms at beginning of treatment (T0) and end of treatment (T2)

THYMUSKIN® effectiveness in patients with chronic telogen effluvium8

  • Hair loss reduced in an average of 99% of patients
  • Seborrhoea and erythema improved in at least 93% of women and 76% of men
  • Itching eliminated in 80% of women and 51% of men

Good to excellent tolerability and cosmetic acceptance

As part of the multicentric study named above8, tolerability and cosmetic acceptance were also evaluated in both patients with androgenetic alopecia and patients with chronic telogen effluvium.

  • Tolerability was excellent in 50% of patients and good in 42%
  • No side effects resulting in termination of treatment were identified
  • Cosmetic acceptance was excellent in 45% of patients, good in 43%, satisfactory in 10% and poor in 2%
Assessment of tolerability and cosmetic acceptance (n-364)

THYMUSKIN® tolerability in patients with androgenetic alopecia or chronic telogen effluvium8

  • Approx. 90% of patients rated tolerability and cosmetic acceptance as ood or excellent

Alopecia areata

Two studies were performed at the Darmstadt Dermatology Clinic9,10 on a total of 36 patients. The first study at the Darmstadt Dermatology Clinic9 investigated Thymuskin’s effectiveness in 16 patients with alopecia areata (AA) over a period of 12 months:

  • 8 women (average age 42.3, average medical history duration 65.5 months)
  • 8 men (average age 30.8, average medical history duration 34.5 months)

The patients exhibited either more than five hairless areas or were suffering from ophiasis-typealopecia. Half of the patients had previously undergone one or more pre-liminary treatments, which offered fleeting success in only two patients.

The patients used Thymuskin shampoo and scalp serum for a period of 12 months: hair shampoo daily for the first two weeks then three times a week, serum twice daily in the first two weeks then once a day in the morning. The success of the treatment was evaluated using subjective assessments by the doctor and patient as well as objective parameters (quantity of hairs falling out per day). The patients experienced a reduction in daily hair loss during the treatment, and the majority of patients experienced renewed hair growth.

1. Reduction in hair loss9

The average number of hairs falling out per day decreased from 245 to 10 by the end of the treatment (a reduction of 96%)

Quantitative hair loss ac-ross a 12-month treatment period

2. New hair growth9

86% of patients demonstrated a subjective improvement in results (new hair growth) at the end of the treatment

Subjective improvement in results by treatment duration

In another study by the Darmstadt Dermatology Clinic10, 20 patients (14 women and 6 men, including 2 children) with A. areata totalis or A. areata universalis used Thymus-kin for a period of 9-24 months.

  • 5 patients with A. areata totalis (average medical history duration 66 months)
  • 15 patients with A. areata universalis (average medical history duration 44.7 months)

Most patients had previously undergone unsuccessful treatment with steroids,diphenylcyclopropenone (DPCP), 4-[(4-aminobenzene)sulfonyl]aniline (dapsone) or PUVA. The patients in the study used Thymuskin Shampoo daily for the first two weeks and then two or three times a week. The scalp serum was used twice daily in the first two weeks and then once a day. After 9-24 months, 65% of patients exhibited new hair growth and 40% of patients were in full remission.

In comparison, treatment with DPCP usually results in full remission being obser-ved in approx. 21-28% of patients.10

3. Full and partial remission10

  • Full remission in 40% of patients: complete growth in scalp region (6/20) or full body hair growth (2/20)
  • Partial remission in 25% of patients: excellent hair growth (2/20) or moderate growth of head and body hairs (3/20)
Clinical findings in 20 patients with alopecia totalis or universalis Full remission in a 40-year-old patient with alopecia areata totalis before and after a year of local treatment with Thymuskin

THYMUSKIN® effectiveness in patients with alopecia areata

  • Number of hairs lost daily reduced by 96%9
  • New hair growth in 65%10-86%9 of patients
  • Full remission in 40% of patients10

Reference list

8. Barbareschi M. et al.: Multizentrische Studie über die Wirksamkeit eines Serums und eines Shampoos zur lokalen Anwendung, die naturidentische Thymus-Peptide enthalten, zur Anwendung bei androgenetischem Haarausfall und chronisch teleogenem Effluvium bei Frauen und Männern. Veröffentlicht 2013 im Journal of Plastic Dermatolo-gy (Ausgabe 9, 2013 · ISSN 2035-0686)

9. Mössler K.: Thymu-Skin: Neuer Therapieansatz bei der Behandlung der Alopecia androgenetica und der Alopecia areata. Der Deutsche Dermatologe 39, Heft 7 (1991)

10. Mössler K., Hagedorn M.: Lokaltherapie mit Thymusextrakt bei Alopecia areata totalis sive universalis. Sonderdruck aus »Der Deutsche Dermatologe« 11/1993, S. 1175-1182